Avelumab and Merkel Cell Carcinoma: Examining Causation

From General Health to Occupational Exposure

For decades, general health and science communication has provided the public with foundational knowledge about disease prevention, treatment options, and the importance of evidence-based medicine. This legacy framework emphasizes broad wellness principles, such as vaccination, screening, and lifestyle modifications, while often simplifying complex biomedical relationships for diverse audiences. Within this context, discussions of pharmaceutical interventions typically focus on therapeutic benefits and common side effects, rarely delving into nuanced risk-benefit analyses for specific populations. Transitioning from this general health perspective to a more specialized occupational exposure concern requires a shift in focus. In mass production settings, workers may encounter a range of chemical and biological agents, including pharmaceutical compounds, as part of their daily duties. The administration of immunotherapies like Avelumab, a PD-L1 inhibitor used in oncology, introduces a distinct exposure scenario for healthcare and manufacturing personnel. While the drug’s primary role is therapeutic, occupational exposure raises questions about potential unintended health effects, including the risk of malignancies such as Merkel Cell Carcinoma. This pivot from patient-centered health information to workplace safety necessitates careful consideration of exposure routes, dose levels, and long-term surveillance, moving beyond general health advice to address specific occupational hazards.

Avelumab and Merkel Cell Carcinoma: A Medical and Risk Narrative

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and incidence rates are increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). This narrative examines whether avelumab causes MCC, focusing on clinical presentation, pharmacology, mechanistic pathways, and risk considerations.

Clinical Presentation and Diagnosis of Merkel Cell Carcinoma

MCC is a rare but highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). It presents as a rapidly growing, painless, firm, dome-shaped nodule, often on sun-exposed skin. Diagnosis is confirmed by histopathology and immunohistochemistry, typically showing cytokeratin 20 positivity. The disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). In advanced stages, systemic therapy options are limited, and response to chemotherapy is not durable (https://pubmed.ncbi.nlm.nih.gov/31543781/).

Avelumab Pharmacology and Reported Adverse Effects

Avelumab is an immune checkpoint inhibitor that blocks PD-L1, thereby enhancing T-cell-mediated antitumor immune responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). Its approval for metastatic MCC was based on the two-part, single-arm, phase II trial, JAVELIN Merkel 200, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported irAEs include hypercalcaemia secondary to reactivation of sarcoidosis, as described in a case report of a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, no evidence in the provided snippets indicates that avelumab causes MCC. Instead, avelumab is a treatment for MCC.

Mechanistic Pathways Linking Avelumab to Merkel Cell Carcinoma

The provided evidence does not describe any mechanistic pathway by which avelumab could cause MCC. On the contrary, avelumab is used to treat MCC by inhibiting PD-L1, which is often exploited by tumors to evade immune surveillance. Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking, though combined ipilimumab plus nivolumab has shown activity in such cases (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Anchors: Adequacy of Warnings, Causation Considerations, and Timeline

Adequacy of Warnings: The evidence snippets do not contain information on specific warnings regarding avelumab and MCC. However, given that avelumab is approved for treating MCC, it is unlikely that warnings would suggest it causes the disease. The risk of progression or lack of response is documented, with about half of patients progressing on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Warnings would appropriately focus on irAEs, such as hypercalcaemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/), rather than causation of MCC. Causation-Related Considerations: For affected patients, the question of whether avelumab causes MCC is not supported by the evidence. Avelumab is a treatment for MCC, and its use is associated with therapeutic responses, not disease induction. Patients who develop MCC while on avelumab likely have pre-existing disease or progression, as the drug is used to treat established MCC. The evidence shows that avelumab-refractory patients may have progressive disease, but this is a failure of treatment, not causation (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Timeline Between Exposure and Documented Harm: The evidence does not provide a timeline for avelumab exposure leading to MCC. In clinical trials, responses to avelumab were observed in patients with pre-existing MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Harm from avelumab is more likely related to irAEs, which can occur during treatment, as seen in the case of hypercalcaemia from sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). The timeline for progression on avelumab is variable, with some patients responding and others progressing, but this reflects disease behavior rather than drug-induced carcinogenesis.

Conclusion

Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. Instead, it is an approved and effective treatment for metastatic MCC. The drug is associated with immune-related adverse events, but no mechanistic or clinical data link it to the development of MCC. For patients, the primary risk is treatment failure or progression of pre-existing disease, not drug-induced carcinogenesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab does not cause Merkel cell carcinoma. It is an approved treatment for metastatic MCC. The evidence shows that avelumab is used to treat MCC by blocking PD-L1, and no mechanistic or clinical data link it to causing the disease.

What are the risks of avelumab treatment?

Avelumab is associated with immune-related adverse events (irAEs) such as hypercalcaemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). Approximately 50% of patients with advanced MCC may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.